Navigating FDA Title 21 CFR Part 11 compliance remains a high-stakes priority for pharmaceutical, biotechnology, and medical device organizations. Regulators continuously issue Form 483s and Warning Letters for data integrity failures, unvalidated systems, and unmonitored audit trails. Identifying these deficiencies early—and implementing robust remediation strategies—is essential for maintaining inspection readiness [...]